HBM Holdings Limited (02142) Announces Non-Exclusive License Agreement with Pfizer

Bulletin Express

Nov 19, 2025

HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks to accelerate antibody discovery in multiple potential disease areas, granting Pfizer global rights to utilize Nona Biosciences’ proprietary HCAb platform to generate fully human heavy chain-only antibodies.

Under the terms of the agreement, Nona Biosciences will receive an upfront payment and may be eligible for regulatory, clinical, and commercial milestone payments. The collaboration could also extend to antibody discovery, development, and engineering, leveraging Nona Biosciences’ HCAb platform and advanced B-cell screening technologies.

According to the announcement, there is no guarantee that HBM Holdings Limited or its collaboration partners will successfully develop or ultimately market the product candidates involved. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares. The board is chaired by Dr. Jingsong Wang, and the announcement is dated November 19, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137995153"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137995153\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137995153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137995153","market":"us","top_or_hot":-1,"title":"HBM Holdings Limited (02142) Announces Non-Exclusive License Agreement with Pfizer","media":"Bulletin Express","content":"<p>HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks to accelerate antibody discovery in multiple potential disease areas, granting Pfizer global rights to utilize Nona Biosciences’ proprietary HCAb platform to generate fully human heavy chain-only antibodies.</p>\n<p>Under the terms of the agreement, Nona Biosciences will receive an upfront payment and may be eligible for regulatory, clinical, and commercial milestone payments. The collaboration could also extend to antibody discovery, development, and engineering, leveraging Nona Biosciences’ HCAb platform and advanced B-cell screening technologies.</p>\n<p>According to the announcement, there is no guarantee that HBM Holdings Limited or its collaboration partners will successfully develop or ultimately market the product candidates involved. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares. The board is chaired by Dr. Jingsong Wang, and the announcement is dated November 19, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Limited (02142) Announces Non-Exclusive License Agreement with Pfizer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Limited (02142) Announces Non-Exclusive License Agreement with Pfizer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-19 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks to accelerate antibody discovery in multiple potential disease areas, granting Pfizer global rights to utilize Nona Biosciences’ proprietary HCAb platform to generate fully human heavy chain-only antibodies.</p>\n<p>Under the terms of the agreement, Nona Biosciences will receive an upfront payment and may be eligible for regulatory, clinical, and commercial milestone payments. The collaboration could also extend to antibody discovery, development, and engineering, leveraging Nona Biosciences’ HCAb platform and advanced B-cell screening technologies.</p>\n<p>According to the announcement, there is no guarantee that HBM Holdings Limited or its collaboration partners will successfully develop or ultimately market the product candidates involved. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares. The board is chaired by Dr. Jingsong Wang, and the announcement is dated November 19, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1137995153","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137995153","pubTimestamp":1763554934,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"和铂医药控股有限公司(02142)公布与辉瑞达成非独家许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings Limited (02142) has announced that its wholly owned subsidiary, Nona Biosciences (Suzhou) Co., Ltd, has entered into a non-exclusive license agreement with Pfizer. The arrangement seeks to accelerate antibody discovery in multiple potential disease areas, granting Pfizer global rights to utilize Nona Biosciences’ proprietary HCAb platform to generate fully human heavy chain-only antibodies.\nUnder the terms of the agreement, Nona Biosciences will receive an upfront payment and may be eligible for regulatory, clinical, and commercial milestone payments. The collaboration could also extend to antibody discovery, development, and engineering, leveraging Nona Biosciences’ HCAb platform and advanced B-cell screening technologies.\nAccording to the announcement, there is no guarantee that HBM Holdings Limited or its collaboration partners will successfully develop or ultimately market the product candidates involved. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares. The board is chaired by Dr. Jingsong Wang, and the announcement is dated November 19, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}